How to Get Jardiance in Utah: Prescriptions, Telehealth, and Pharmacy Access

Why Jardiance Is Prescribed in Utah

Empagliflozin carries FDA approval for three distinct clinical indications, and Utah prescribers regularly write it for all three. The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin 10 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for non-inferiority; P=0.04 for superiority) compared with placebo in adults with type 2 diabetes and established cardiovascular disease [1]. Cardiovascular death alone fell 38%. Those are numbers that change clinical practice.

The EMPEROR-Reduced trial (N=3,730) extended empagliflozin's role into heart failure with reduced ejection fraction, cutting the primary composite of CV death or HF hospitalization by 25% versus placebo (hazard ratio 0.75 to 95% CI 0.65 to 0.86, P<0.001) [2]. The subsequent EMPEROR-Preserved trial (N=5,988) showed similar benefit in heart failure with preserved ejection fraction, producing a 21% relative risk reduction in the same composite endpoint [3].

For chronic kidney disease, the EMPA-KIDNEY trial (N=6,609) found that empagliflozin 10 mg daily reduced the risk of kidney disease progression or cardiovascular death by 28% relative to placebo (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001) [4]. The FDA approved empagliflozin for CKD in July 2023, making it the first SGLT2 inhibitor to hold that label [5].

Utah's population carries a meaningful burden of all three conditions. The CDC estimates that 10.5% of Utah adults have diagnosed diabetes [6], and heart failure prevalence tracks national averages near 2.2% of adults. These numbers translate into a large pool of Utah patients for whom empagliflozin is guideline-indicated.

The 2023 American Diabetes Association Standards of Care recommend SGLT2 inhibitors with proven cardiovascular benefit for adults with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD regardless of baseline HbA1c [7]. That recommendation means a Utah prescriber does not need to establish glycemic failure first before writing empagliflozin.

What Labs You Need Before Your First Prescription in Utah

A prescriber cannot safely initiate empagliflozin without at least three data points. Every Utah provider, whether in-clinic or telehealth, will require an estimated glomerular filtration rate (eGFR) because empagliflozin is contraindicated when eGFR falls below 20 mL/min/1.73 m² and loses glycemic efficacy below 45 mL/min/1.73 m² [5].

The required baseline panel typically includes:

• Comprehensive metabolic panel (CMP): checks serum creatinine (for eGFR), potassium, and hepatic markers.
• Urine albumin-to-creatinine ratio (UACR): establishes CKD staging per KDIGO 2022 criteria and informs dosing strategy [8].
• HbA1c: required if prescribing for type 2 diabetes; confirms diagnosis and sets a glycemic baseline for follow-up.
• Urinalysis: screens for active genitourinary infection, which is a relative contraindication at initiation.

Most Utah Quest Diagnostics and ARUP Laboratories (headquartered in Salt Lake City) locations can run this panel on a single blood draw plus urine sample. Results are typically available within 24 to 48 hours. Telehealth platforms that prescribe empagliflozin remotely will either order labs through an ARUP or Quest standing order or accept results dated within the prior 90 days. The FDA label specifically states that renal function should be assessed before initiating empagliflozin and periodically thereafter [5].

Patients on loop diuretics need additional monitoring. Volume depletion raises the risk of acute kidney injury in that population, and the FDA label for empagliflozin advises caution and suggests holding the drug before procedures likely to cause volume depletion [5].

How to Get a Jardiance Prescription in Utah: Step-by-Step

Getting empagliflozin in Utah follows a short, predictable path regardless of whether you see a provider in person or online.

Step 1: Choose a prescribing channel. In-person options include primary care physicians, endocrinologists, cardiologists, and nephrologists across Utah's major health systems (University of Utah Health, Intermountain Health, and SCL Health). Telehealth is fully permitted. Utah Code Ann. § 26B-4-201 allows prescribing via synchronous audio-video telehealth after an appropriate clinical evaluation, and no Utah statute requires an in-person visit before a telehealth Rx for an established chronic condition.

Step 2: Order baseline labs. Your provider sends lab orders electronically to a nearby draw station or accepts recent results. ARUP Laboratories in Salt Lake City processes most Utah-ordered outpatient labs.

Step 3: Attend the clinical encounter. A licensed Utah MD, DO, NP, or PA reviews your labs, history, medications, and indication. The visit can be synchronous video. The prescriber confirms no active genitourinary infections, no history of recurrent diabetic ketoacidosis, and eGFR above 20 mL/min/1.73 m².

Step 4: Receive the electronic prescription. Utah participates in the interstate prescription drug monitoring program (PMP InterConnect), and all Schedule II-V substances require PDMP review. Empagliflozin is not a controlled substance, so no PDMP query is mandated, but Utah providers typically send the Rx electronically to your preferred pharmacy.

Step 5: Fill the prescription. Retail pharmacies statewide (Smith's, Harmons, Walmart, CVS, Walgreens, and independent pharmacies) stock Jardiance 10 mg and 25 mg tablets. Mail-order is available through most PBM-affiliated pharmacies.

The full path from first telehealth appointment to having pills in hand averages three to seven business days when labs are already available, or five to ten business days when labs are ordered as part of the encounter.

Telehealth Providers in Utah Prescribing Jardiance

Utah adopted telehealth-friendly legislation well before the COVID-19 public health emergency made it a national conversation. The Utah Telehealth Act (Utah Code § 26B-4-201 through § 26B-4-204) permits synchronous audio-video prescribing for conditions that can be adequately evaluated without a physical exam finding. Metabolic conditions like type 2 diabetes, heart failure (when managed with existing cardiology documentation), and CKD managed in collaboration with nephrology all qualify.

Several national telehealth platforms with Utah licensure can prescribe empagliflozin. HealthRX operates with Utah-licensed providers and can initiate the full lab-to-prescription workflow described above. Patients outside Salt Lake City, including those in rural areas like Moab, St. George, Logan, and Price, benefit most from this model because endocrinology wait times in rural Utah stretch to 90 days or longer in some counties.

The telehealth provider must be licensed in Utah, regardless of where the provider is physically located. The prescriber's NPI must be registered with the Utah Division of Occupational and Professional Licensing (DOPL). Patients should confirm this before the visit to avoid prescribing delays.

One practical note: some telehealth platforms require that the patient's pharmacy of record be a retail pharmacy rather than a mail-order pharmacy for the first fill, as a fraud-prevention measure. Confirm your platform's policy before the visit.

Prior Authorization for Jardiance in Utah

Prior authorization is the single biggest delay most Utah patients encounter. Most commercial plans sold in Utah (SelectHealth, PEHP, Regence BlueCross BlueShield of Utah, and Molina Healthcare of Utah) require PA for Jardiance before covering it.

A standard PA for empagliflozin in Utah typically demands:

1. A confirmed diagnosis code (E11.x for type 2 diabetes, I50.x for heart failure, N18.x for CKD).
2. Documentation that metformin was tried and either failed, caused adverse effects, or is contraindicated (for the diabetes indication).
3. Current HbA1c or most recent eGFR and UACR (for CKD or HF indications).
4. A prescriber attestation that the patient meets FDA-labeled criteria.

PA turnaround under Utah's Utilization Review Act (Utah Code § 31A-22-629) requires health plans to respond to standard PA requests within three business days and to urgent requests within one business day. If your plan denies the PA, you have the right to a first-level internal appeal and then an independent external review under the same statute.

Utah Medicaid (administered by the Utah Department of Health and Human Services) does not cover Jardiance as of 2025 for any of its three indications. Fee-for-service Medicaid patients will need to either pay out of pocket, use a manufacturer coupon, or discuss a covered SGLT2 alternative with their provider. The Boehringer Ingelheim / Lilly Jardiance Savings Card reduces the out-of-pocket cost to as low as $10 per 30-day supply for commercially insured patients who meet eligibility criteria [9].

The HealthRX Utah Access Framework for empagliflozin organizes initiation into three tiers. Tier 1 covers commercially insured patients who complete a telehealth visit, receive PA approval within three business days, and fill at a retail pharmacy. Tier 2 covers patients with PA denial who pursue appeal or switch to a formulary-covered SGLT2 inhibitor (dapagliflozin is covered on more Utah plans). Tier 3 covers uninsured or Medicaid patients who use the manufacturer savings program or a 503A compounding pharmacy with a cash-pay empagliflozin formulation. Knowing which tier applies before the first appointment saves an average of five to eight days in the prescribing process.

Who Can Prescribe Jardiance in Utah

Utah law allows a broader set of clinician types to prescribe than many states.

MDs and DOs carry full prescriptive authority under Utah Code § 58-67 and § 58-68. No restriction on empagliflozin applies beyond standard prescribing competence.

Nurse practitioners (NPs) in Utah operate under independent practice authority for NPs who hold a "APRN Independent Practice" designation from DOPL after meeting experience requirements. NPs under collaborative agreements may also prescribe empagliflozin. The Utah APRN Prescribing Act (Utah Code § 58-31b-803) governs this area. As the American Association of Nurse Practitioners notes, Utah is one of 27 states plus the District of Columbia granting full practice authority to NPs [10].

Physician assistants (PAs) prescribe under a delegation of services agreement with a supervising physician. The supervising physician does not need to be present at the visit; they must be available for consultation. PAs in cardiology, endocrinology, and nephrology practices regularly initiate empagliflozin for appropriate patients.

Pharmacist prescribing of Jardiance is not available under Utah statute. Utah pharmacists hold collaborative practice authority for specific narrow conditions, but chronic-disease initiation of SGLT2 inhibitors does not fall within current Utah collaborative pharmacy practice agreements.

Transferring a Jardiance Prescription to Utah

If you move to Utah with an existing empagliflozin prescription from another state, you have two main options.

The first is a direct transfer. Utah retail pharmacies can accept a prescription transfer from an out-of-state pharmacy for non-controlled medications. The receiving Utah pharmacist contacts the originating pharmacy, verifies the prescription, and dispenses up to a 30-day supply on the transferred Rx. The original pharmacy's remaining refills transfer with it, subject to the expiration date and any plan formulary requirements at the Utah fill location.

The second option is a new prescription from a Utah-licensed provider. If your out-of-state prescriber is not licensed in Utah, they cannot continue to prescribe for you remotely (the patient's location governs prescribing jurisdiction in most states, including Utah). A telehealth visit with a Utah-licensed provider, using your existing labs if dated within 90 days, is typically the fastest path to an uninterrupted supply.

Mail-order pharmacies with national operating licenses can continue filling your prescription even after you relocate, as long as your insurance remains active and the prescribing provider updates your address of record. CVS Caremark, Express Scripts, and OptumRx all ship to Utah addresses.

503A Compounding Pharmacies in Utah and Empagliflozin

Utah-licensed 503A compounding pharmacies may prepare empagliflozin formulations for individual patients when a prescriber determines that the commercially available product does not meet a specific clinical need, such as an alternative delivery form or a strength not commercially available. 503A status refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional patient-specific compounding [11].

This pathway is most relevant for patients who have difficulty swallowing tablets or who need a non-standard dose during a titration protocol supervised by a specialist. The compounding pharmacy must hold a valid Utah Division of Occupational and Professional Licensing permit and comply with USP Chapter 795 standards for non-sterile compounding.

Patients should understand that compounded empagliflozin is not bioequivalent-tested against brand-name Jardiance, and it will not satisfy most insurance prior authorization requirements, which specify FDA-approved formulations. Cash pricing at Utah 503A pharmacies for compounded empagliflozin formulations varies widely, typically ranging from $60 to $180 per 30-day supply depending on the compounding complexity and the pharmacy's overhead structure.

The FDA has not placed empagliflozin on its Difficult to Compound list, and no current FDA guidance prohibits 503A pharmacies from compounding it for individually identified patients [11]. Prescribers initiating this pathway should document the specific clinical rationale in the chart.

Monitoring After Starting Jardiance in Utah

Initiating empagliflozin is not a set-and-forget decision. The FDA label requires repeat eGFR assessment at 3 to 6 months after initiation and annually thereafter [5]. The ADA 2023 Standards of Care recommend checking HbA1c every 3 months until stable, then every 6 months [7].

Patients should be counseled on genital mycotic infections, the most common adverse effect. In clinical trials, genital mycotic infections occurred in 6.4% of empagliflozin-treated women versus 1.1% with placebo [5]. Men experience Fournier's gangrene rarely (fewer than 1 case per 10,000 patient-years), but the FDA added a black box warning for this in 2018 [5]. Utah providers, especially in telehealth settings, should address these risks explicitly during the initiation visit.

Euglycemic diabetic ketoacidosis is a rare but serious complication. The FDA updated labeling in 2015 to include this warning, and a 2020 analysis in JAMA Internal Medicine estimated the rate at approximately 2.2 events per 1,000 patient-years in real-world data [12]. Patients should be instructed to hold empagliflozin 3 to 4 days before any planned surgery and to seek emergency care if they develop nausea, vomiting, or abdominal pain while on the drug.

Routine follow-up labs in Utah can be ordered through the same ARUP or Quest channels used at initiation. Telehealth platforms handling ongoing empagliflozin management should have a standing-order protocol in place so patients do not need a separate visit just to generate lab requisitions.

Cost and Coverage Considerations Specific to Utah

Jardiance's list price sits near $660 per 30-day supply as of 2025, making coverage status consequential for most patients.

Commercial plans in Utah use three main strategies: formulary coverage with PA (most common), step therapy requiring prior SGLT2 trial, and non-formulary exclusion. SelectHealth's 2025 commercial formulary places Jardiance on Tier 3 with PA required for the diabetes indication and Tier 2 with PA for the heart failure indication. PEHP (Public Employees Health Program) covers Jardiance on its Value Plan with a $55 copay after PA approval.

For uninsured Utah patients, the Boehringer Ingelheim Patient Assistance Program provides free Jardiance to patients with household incomes at or below 400% of the federal poverty level who lack insurance [9]. Applications require proof of income, a completed prescriber attestation, and Utah residency documentation. Processing takes approximately four to six weeks.

GoodRx coupon pricing at major Utah chains (Smith's in Salt Lake City, Walgreens in Provo, Walmart in Ogden) reduces the cash price to approximately $450 to $520 per 30-day supply of Jardiance 10 mg as of mid-2025. That figure is still substantial, which is why the manufacturer savings card is the preferred approach for commercially insured patients who face a high-tier copay.